Clinical Trial

Opioidergic and Noradrenergic Systems in Central Parkisonian Pain

Study acronym: PAINPARK
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 17, 2025 (before its estimated October 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this study is to evaluate the differences in functional physiopathology of the opioid and noradrenergic systems between Parkinson's patients with central pain and Parkinson's patients without central pain. Using PET-MRI data, investigators aim to observe opioids receptors availability using \[11C\]Carfentanil (µ opioid receptor agonist) and altered α2-AR density with \[11C\]Yohimbine (adrenergic α2 receptor antagonist).
Trial Details
NCT Number NCT07127146
Lead Sponsor Hospices Civils de Lyon
Conditions Parkinson Disease
Enrollment 55 participants
Start Date 2025-10-01
Primary Completion 2025-10-01 (estimated)
Study Completion 2025-10-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-17